Houston student startup competition doles out record-breaking more than $3M in prizes

show me the money

Seventeen of the RBPC student teams walked away with investment prizes this year. Photo courtesy of Rice

Over the weekend, Houston hosted what is known as the world’s largest and richest intercollegiate student startup competition, and a Texas team took the overall win and over $3 million in investment prizes were given out at the annual banquet.

The 2023 Rice Business Plan Competition was held May 11-13 and included mentoring, pitching, and networking for the 42 student teams with over 350 judges before culminating in over 80 prizes being announced. The $3.4 million in investment and in-kind prizes marks the largest yet for the 23-year-old competition.

"Judges told us that the quality of the startups at this year’s competition was the best ever,” says Catherine Santamaria, director of the RBPC, in the news release. “One judge went so far as to say that every startup this year was worthy of investment.”

Over 450 startups applied to the competition, and the 42 startups selected hailed from 35 universities from five countries. There were five categories: energy, clean tech and sustainability; life sciences and health care solutions; consumer products and services; hard tech; and digital enterprise. Based on the judges scores, seven startups reached the finals, and this year, three Texas teams made the finals, with two being from Rice University.

All 42 companies were eligible for investment or in-kind prizes, and, even though $1.75 million in prizes was expected to be awarded, some of this year's investors doubled — or even tripled — down on investment awards. While the finalists walked away with various in-kind prizes too, here's a round up of the investment prizes each startup won at the awards.

Zaymo, Brigham Young University — $885,000

Zaymo, a tool for e-commerce brands that embeds the shopping experience within customers’ email, won the most amount of money at the awards ceremony. The company won third place and a $50,000 Investment Prize sponsored by David Anderson, Jon Finger, Anderson Family Fund, Finger Interests, Greg Novak and Tracy Druce. Zaymo also won the following awards:

  • $200,000 OWL Investment Prize
  • $100,000 Houston Angel Network Investment Prize
  • $500,000 Softeq Venture Fund Prize
  • $15,000 Eagle Investors Prize
  • $20,000 Novak Druce Carroll Investment Prize

Boston Quantum, Massachusetts Institute of Technology — $455,000

Boston Quantum, which is using enterprise quantum computing software to disrupt the financial industry, won the second-most amount of investment prizes and sixth place in the competition.

  • $5,000 Chevron Technology Ventures Sixth-Place Cash Prize
  • $300,000 OWL Investment Prize
  • $125,000 Softeq Venture Fund Prize
  • $25,000 Urban Capital Network Diversity Investment Prize in partnership with South Loop Ventures

FluxWorks, Texas A&M University — $350,000

Based on the judges scores, the big winner was FluxWorks, a Texas company that's technology includes magnetic gears that are four times quieter than standard with 99 percent efficiency and can offer unprecedented reliability from outer space to under the sea and even inside the human body. The company won the $350,000 GOOSE Capital Investment Grand Prize.

Skali, Northwestern University — $300,000

Skali, which didn't make it into the prestigious finalist positions, still walked away with $300,000 courtesy of the Softeq Venture Fund Prize. Skali's technology aims to better equip flights with medical emergency assistance.

TierraClimate, Rice University — $280,000

TierraClimate, a marketplace for selling verified carbon offsets to corporate buyers, won fourth place and the Norton Rose Fulbright $5,000 Prize. The company also won a $200,000 Softeq Venture Fund Prize and the $75,000 OWL Investment Prize.

AirSeal, Washington University in St. Louis — $250,000

Another non-finalist that still scored big was AirSeal, a company that's created a simple blood test for cardiovascular diagnostics. The startup secured the $250,000 TMC Innovation Healthcare Investment Prize.

Sygne Solutions, Rice University — $200,000

Sygne Solutions, a startup on a mission of eliminating a group of chemicals known as PFAS in water through its patent-pending technology, won second place and the $100,000 Investment Prize, sponsored by David Anderson, Jon Finger, Anderson Family Fund, Finger Interests, Greg Novak and Tracy Druce. The company also received the $100,000 TiE Houston Angels Investment Prize.

BlueVerse, Texas Tech University — $145,000

BlueVerse, a startup with tech to merge social media with reviews and rewards for small businesses, didn't make the finals but walked away with on of the $125,000 Softeq Venture Fund Prizes and the $20,000 Novak Druce Carroll Investment Prize.

Atma Leather, Yale University —$130,000

Atma Leather, a material innovation company that's created plant-based leather from banana stems and other crop waste, came in fifth place and secured the $5,000 EY Fifth-Place Cash Prize. The startup also won:

  • $75,000 OWL Investment Prizes
  • $50,000 nCourage Investment Group’s Courageous Women Entrepreneurs Investment Prize

MyLÚA Health, Cornell University — $30,000

MyLÚA Health's AI technology supports the maternal health industry. The company won the $30,000 Pearland Economic Development Corporation Spirit of Entrepreneurship Prize.

Active Surfaces, Massachusetts Institute of Technology — $25,000

With its flexible and lightweight solar panel technology, Active Surfaces scored the $25,000 New Climate Ventures Sustainability Investment Prize.

Integrated Molecular Innovations, Michigan Technological University — $25,000

Integrated Molecular Innovations, which created a wearable device that can monitor hormone levels, won the $25,000 Southwest National Pediatric Device Consortium Prize.

MiraHeart, Johns Hopkins University — $25,000

MiraHeart, which created a non-invasive way of monitoring child heart conditions, also won the $25,000 Southwest National Pediatric Device Consortium Prize.

Biome Future, University of Florida — $20,000

Biome Future, which creates ocean-safe chemicals via microbes in corals, won one of the $20,000 Novak Druce Carroll Investment Prizes.

Citrimer, University of Michigan — $10,000

A sustainable materials company, Citrimer won the $10,000 NABACO RBPC Alumni Network Prize.

Thryft Ship, University of Georgia — $10,000

Thryft Ship, which streamlines the shipping process for social media sellers, won a $10,000 nCourage Investment Group’s Courageous Women Entrepreneurs Investment Prize.

Pathways, Harvard University  — $5,000

Pathways, which is developing a full-stack sustainability platform for the construction industry, won $5,000 Shell Ventures Seventh-Place Cash Prize.

In addition to these investment prizes, the startups have the chance to score in-kind prizes. This year, that included:

  • $6,667 Baker Botts Legal Services In-Kind Prize to FluxWorks, Texas A&M University
  • $6,667 Baker Botts Legal Services In-Kind Prize to Sygne Solutions, Rice University
  • $6,667 Baker Botts Legal Services In-Kind PrizeFluxWorks to Zaymo, Brigham Young University
  • $10,000 New York Technology Capital CFO Consulting In-Kind to FluxWorks, Texas A&M University
  • EFN Mentoring Services to all startup competitors
  • Amazon Web Services to all startup competitors
  • Stage 2 Competition Entry to Sygne Solutions, Rice University
All 42 of the RBPC companies wins at least $950. In each of the three semi-final rounds, third place wins $2,000, fourth place wins $1,750, and fifth place wins $1,500. The wild card round, which acts as a second-chance competition for the companies that didn't originally make it to the finals, advances the wild card winner into the finals and also awards second place $1,000, third place $975, fourth place $950, and fifth place $950.
From Your Site Articles
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston digital health platform Koda lands strategic investment

money moves

Houston-based advance care planning platform Koda Health has added another investor to the lineup.

The company secured a strategic investment for an undisclosed amount from UPMC Enterprises, the commercialization arm of the University of Pittsburgh Medical Center. The funding is part of Koda's oversubscribed series A funding round that closed in October, according to a release.

"UPMC Enterprises’ investment is a meaningful signal, not just to Koda, but to the broader market," Dr. Desh Mohan, chief medical officer and co-founder of Koda Health, said in the news release. "It validates that health systems are ready to invest in infrastructure that makes advance care planning work the way it should: proactively, at scale, and with the human support that these conversations require. Having UPMC Enterprises as a strategic investor puts us in a unique position to prove what's possible."

Koda has raised $14 million to date, according to a representative from the company. Its series A round was led by Evidenced, with participation from Mudita Venture Partners, Techstars and the Texas Medical Center last year. At the time, the company said the funding would allow it to scale operations and expand engineering, clinical strategy and customer success. The company described the round as a "pivotal moment," as it had secured investments from influential leaders in the healthcare and venture capital space.

Koda Health, which was born out of the TMC's Biodesign Fellowship in 2020, saw major growth last year, as well, and now supports more than 1 million patients nationwide through partnerships with Cigna Healthcare, Privia Health, Guidehealth, Sentara, UPMC and Memorial Hermann Health System.

The company integrated its end-of-life care planning platform with Dallas-based Guidehealth in April 2025 and with Epic Systems in July 2025. It also won the 2025 Houston Innovation Award in the Health Tech Business category. Read more here.

UH med school gets $2M gift and more top Houston innovation news

Trending Topics

Editor's note: The top Houston innovation news of the month is full of fresh funding, with two Texas medical schools receiving major gifts — one of historic proportions. Below are the five most-read InnovationMap headlines from April 16-30, 2026.

UH med school granted $2M gift to offer student scholarships

A new scholarship endowment aims to support students in the University of Houston’s recently established medical school. The University of Houston’s Tilman J. Fertitta Family College of Medicine received a planned estate gift commitment estimated at $2.1 million to establish the Bob Diehl and Teresa Evans Diehl Scholarship Endowment. The scholarship will assist full-time medical students who demonstrate financial need and meet academic standards. Continue reading.

How Houston innovators played a role in the historic Artemis II splashdown

Research from Rice University played a critical role in the safe return of U.S. astronauts aboard NASA’s Artemis II mission this month. Rice mechanical engineer Tayfun E. Tezduyar and longtime collaborator Kenji Takizawa developed a key computational parachute fluid-structure interaction (FSI) analysis system that proved vital in NASA’s Orion capsule’s descent into the Pacific Ocean. The FSI system, originally developed in 2013 alongside NASA Johnson Space Center, was critical in Orion’s three-parachute design, which slowed the capsule as it returned to Earth, according to Rice. Continue reading.

Baylor scientist lands $2M grant to explore links between viruses and Alzheimer’s

A Baylor College of Medicine scientist will begin exploring the possible link between Alzheimer’s disease and viral infections thanks to a $2 million grant awarded in March. Dr. Ryan S. Dhindsa hypothesizes that Alzheimer’s may have some link to previous viral infections contracted by the patient. To study this intriguing possibility, the American Brain Foundation has gifted him the Cure One, Cure Many award in neuroinflammation. Continue reading.

New UT Austin med center, anchored by MD Anderson, gets historic gift

A donation announced April 21 breaks a major record at the University of Texas at Austin. Michael and Susan Dell are now UT Austin's first supporters to give $1 billion. In response, the university will create the UT Dell Campus for Advanced Research and the UT Dell Medical Center to "advance human health," per a press release. Continue reading.

Houston VC funding surged nearly 50% in Q1 2026, report says

Houston saw a jump in VC funding in Q1 2026, fueled by several major investments in clean energy startups. Image via Getty Images

First-quarter venture capital funding for Houston-area startups climbed nearly 50 percent compared to the same time last year, according to the PitchBook-NVCA Venture Monitor. In Q1 2026, Houston-area startups raised $532.3 million, a 49 percent jump from $320.2 million in Q1 2025, according to the PitchBook-NVCA Venture Monitor. However, the Q1 total fell 23 percent from the $671.05 million raised in Q4 2025. Continue reading.

New 'living pharmacy' biotech company launches out of Rice venture studio

fighting cancer

Rice University’s biotech venture studio RBL LLC has launched a new “living pharmacy” company, Duracyte, designed to make cancer treatment easier on patients.

Backed by an up to $45 million Advanced Research Projects Agency for Health (ARPA-H) award, Duracyte aims to commercialize implantable biohybrid pharmacy devices that are designed to produce therapeutic proteins inside the human body around the clock, replacing the need for regular injections and infusions for some cancer patients.

The company’s main platform is its Hybrid Advanced Molecular Manufacturing Regulator (HAMMR), a rechargeable, implantable device that can sense biological signals, monitor tumor environments and adjust therapeutic output in real time. HAMMR has wireless communication capabilities, which allow patients and clinicians to remotely monitor results through an app every five minutes and make changes to treatment plans without a hosptial visit. Additionally, the device can generate its own oxygen supply, which is key for the therapeutic cells’ survival.

“Biologic medicines such as monoclonal antibodies, cytokines and metabolic regulators already account for a significant share of modern therapeutics, but the way we deliver them today often requires frequent injections or infusions that can be demanding for patients and lead to inconsistent drug levels,” Daniel Anderson, MIT professor and co-founder of Duracyte, said in a news release. “Our vision is to enable a continuous, stable therapy by producing these medicines directly inside the body, which could improve treatment consistency, reduce side effects and ultimately transform how biologic therapies are delivered across many diseases.”

Duracyte’s first clinical trial is slated to begin by the end of 2026 and will focus on recurrent ovarian cancer. The Phase I study will build upon existing work on encapsulated cytokine pharmacy technology, and the company hopes that within a few years this treatment can reach clinical application.

The development of Duracyte is supported by ARPA-H's Targeted Hybrid Oncotherapeutic Regulation (THOR) project, which supports a multidisciplinary research consortium co-led by Omid Veiseh, a professor of bioengineering at Rice. The consortium also includes others at Rice, The University of Texas MD Anderson Cancer Center, Stanford University, Carnegie Mellon University, Northwestern University and the University of Houston, plus industry collaborators like Chicago-based CellTrans.

“What we are building is the culmination of years of progress in cell engineering, biomaterials and implantable device technology,” Veiseh added in the release. “By combining these advances with real-time sensing and adaptive drug delivery, we are working with the support of RBL to create a true ‘living pharmacy’ that can deliver continuous, precisely controlled biologic therapies and fundamentally change how these treatments reach patients.”

RBL launched in 2024 and is based out of Houston’s Texas Medical Center Helix Park. Duracyte is the third company launched by RBL, including Sentinel BioTherapeutics, a clinical-stage immunotherapy company developing localized cytokine therapies for solid tumors, and SteerBio, a regenerative medicine company targeting lymphedema.

“Duracyte exemplifies the kind of breakthrough that Houston’s ecosystem is built to produce,” Paul Wotton, managing partner of RBL LLC and co-founder of Duracyte, added in the release. “With world-class clinical infrastructure, exceptional engineering talent and initiatives like the Texas Biotech Task Force driving alignment across industry, investment and talent, this region is uniquely positioned to move the most ambitious ideas in medicine from concept to patient, faster than anywhere else.”

View All Listings